News
CERE
42.59
-0.09%
-0.04
Cerevel Therapeutics Holdings Inc <CERE.OQ> expected to post a loss of 61 cents a share - Earnings Preview
Cerevel Therapeutics Holdings Inc expected to post a loss of 61 cents a share. The company is expected to show change in quarterly revenue when it reports results on May 1. Average analyst rating on the shares is "hold" and the median 12-month price target is $45.
Reuters · 4d ago
Weekly Report: what happened at CERE last week (0422-0426)?
Weekly Report · 4d ago
Polaris Global Equity Composite Q1 2024 Commentary
Global equity markets enjoyed consecutive months of gains, with the MSCI World Index returning 9.01% for the quarter. The Polaris Global Equity Composite returned 6.19% (net of fees), lagging the benchmark. Global portfolio had absolute positive gains across all sectors, led by financials, industrials and consumer discretionary holdings.
Seeking Alpha · 04/25 12:00
Weekly Report: what happened at CERE last week (0415-0419)?
Weekly Report · 04/22 12:04
Hold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie Acquisition
TipRanks · 04/22 06:45
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Cerevel Therapeutics Holdings Inc. Released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The trial met its primary endpoint. The drug is an adjunctive therapy to levodopa in adults.
Benzinga · 04/18 17:44
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 04/18 17:35
BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
Dow Jones Industrial Average was up 0.52% on Thursday. The benchmark S&P 500 and the Nasdaq were subdued as higher Treasury yields pressured equities. Zscaler, Las Vegas Sands, 23andMe and Ally Financial were among the day's top stocks.
Reuters · 04/18 16:32
Heard on the Street: AbbVie's Bet on a Neuroscience Drug Maker Just Got Better
AbbVie's Parkinsons disease drug performed well in a late-stage study. The drug is part of a new class of psychiatric drugs. Abbvie bought neuroscience biotech Cerevel Therapeutics in December for $8.7 billion. The Federal Trade Commission has been reviewing the deal.
The Wall Street Journal · 04/18 16:17
BUZZ-U.S. STOCKS ON THE MOVE-D.R. Horton, 23andMe, Copper miners
D.R. Horton, 23andMe, Copper miners rise as chip stocks rebound. Dow e-minis expected to open higher on Thursday. Investors await commentary from Federal Reserve officials on outlook for interest-rate cuts. 23andme rises after CEO considers taking firm private.
Reuters · 04/18 13:13
Health Care Sector Update for 04/18/2024: ELV, CERE, BHVN, XLV, IBB
NASDAQ · 04/18 13:12
BUZZ-Cerevel rises as Parkinson's drug improves symptom control in late-stage trial
Shares of drug developer Cerevel Therapeutics rise 1.4% to $42.20 premarket. Cerevel says Parkinson's drug improves symptom control in late-stage trial. Company says drug tavapadon improved symptoms control in Parkinson's disease patients.
Reuters · 04/18 12:10
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
Seeking Alpha · 04/18 11:00
UPDATE 1-Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study. Trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson's. Cerevel's drug met the main goal of a late stage trial.
Reuters · 04/18 10:51
UPDATE 2-Cerevel's Parkinson's disease drug improves symptom control in late-stage trial
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial. Drug tested as an add-on therapy to levodopa. The disease affects about 1 million people in the United States. AbbVie agreed to buy Cerevel Therapeutics in December for $8.7 billion.
Reuters · 04/18 10:51
CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS GENERALLY WELL TOLERATED
Reuters · 04/18 10:30
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Barchart · 04/18 05:30
Weekly Report: what happened at CERE last week (0408-0412)?
Weekly Report · 04/15 11:54
Weekly Report: what happened at CERE last week (0401-0405)?
Weekly Report · 04/08 12:01
AbbVie slips after revising guidance to reflect earnings impact
Healthcare AbbVie slips after revising guidance to reflect earnings impact. The company's stock posted its biggest intraday decline in more than five months on Thursday. The pharma giant revised its full-year and Q1 2024 guidance to include an unfavorable impact on earnings.
Seeking Alpha · 04/04 19:12
More
Webull provides a variety of real-time CERE stock news. You can receive the latest news about Cerevel Therapeutics Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About CERE
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.